Biocon founder and chairperson Kiran Mazumdar Shaw has outlined a gradual leadership transition plan, naming her niece Claire Mazumdar as her successor, with a phased handover expected over the next five years.
Mazumdar Shaw clarified that she does not plan an immediate exit but intends to oversee a structured transition, where Claire will move step-by-step from a board level role to vice-chair and eventually chairperson.
Claire Mazumdar currently serves as the founding CEO of Bicara Therapeutics, an oncology focused biotech firm incubated with early backing from Mazumdar Shaw. Her experience spans biotech strategy, company building, and partnerships, having previously worked at Rheos Medicines and Third Rock Ventures, where she was involved in company formation and strategic development.
The planned succession reflects a continuity driven approach, ensuring leadership stability at one of India’s leading biopharmaceutical companies. Biocon has grown into a global player in biosimilars, generics, and research driven biotechnology under Mazumdar Shaw’s leadership.
The transition also signals a long-term succession strategy rather than an abrupt change, allowing time for alignment with the company’s evolving global ambitions.
Mazumdar Shaw reiterated that the process will be phased and deliberate, ensuring that Claire gains deeper exposure to Biocon’s operations, governance, and strategic direction before assuming full leadership.
The move comes at a time when biotech companies are increasingly focusing on innovation-led growth and global expansion, making leadership continuity critical.
Build smarter. Learn faster. Grow stronger with StartupByDoc.